Home › Funds › HIMENSION CAPITAL (SINGAPORE) PTE. LTD. › ALNY

HIMENSION CAPITAL (SINGAPORE) PTE. LTD. position in ALNY

ALNYLAM PHARMACEUTICALS INC · Health Care

HIMENSION CAPITAL (SINGAPORE) PTE. LTD. reported holding 18,589 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$4.6M, representing 0.31% of its reported portfolio and ranking #32 among its reported holdings. HIMENSION CAPITAL (SINGAPORE) PTE. LTD. has disclosed ALNY holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)18.59K sh
Reported value held$4.59M
Portfolio Weight0.31%
First reportedQ4 2024
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How HIMENSION CAPITAL (SINGAPORE) PTE. LTD.'s ALNY position evolved

HIMENSION CAPITAL (SINGAPORE) PTE. LTD. first disclosed a stake in ALNY in Q4 2024 at 4,529 shares (US$1.1M). The position peaked in Q2 2026 at 18,136 shares, worth US$5.5M. Across 8 filings, HIMENSION CAPITAL (SINGAPORE) PTE. LTD. increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 18,589 shares valued at US$4.6M — an increase of 453 shares quarter over quarter.. Notable position changes include a 238% increase in Q1 2025 (shares rose 20% over the following quarter), a 29% increase in Q1 2026 (shares fell 8% over the following quarter), a 38% increase in Q2 2026 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 4.53K $1.07M New
Q1 2025 15.30K $4.13M Add
Q2 2025 13.49K $4.40M Reduce
Q3 2025 10.09K $4.60M Reduce
Q4 2025 10.19K $4.05M Add
Q1 2026 13.17K $4.36M Add
Q2 2026 18.14K $5.46M Add
Q3 2026 18.59K $4.59M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ALNY and 13F data

ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALNY

All ALNY fund holders →

FAQ

How long has HIMENSION CAPITAL (SINGAPORE) PTE. LTD. held ALNY?

HIMENSION CAPITAL (SINGAPORE) PTE. LTD. has disclosed ALNY holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is HIMENSION CAPITAL (SINGAPORE) PTE. LTD.'s current position in ALNY?

As of Q3 2026, HIMENSION CAPITAL (SINGAPORE) PTE. LTD. holds 18.59K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $4.59M, representing 0.31% of its reported portfolio and ranking #32.

Has HIMENSION CAPITAL (SINGAPORE) PTE. LTD. been buying or selling ALNY?

In the latest 13F filing (Q3 2026), HIMENSION CAPITAL (SINGAPORE) PTE. LTD. increased its position in ALNY. The position peaked in Q2 2026 at 18.14K shares.

Which other funds hold ALNY?

Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.